Evelo Biosciences Inc
NASDAQ:EVLO
Evelo Biosciences Inc
NASDAQ:EVLO
Price:
0.001 USD
-97.56%
Updated:
May 21, 2024
Balance Sheet
Balance Sheet Decomposition
Evelo Biosciences Inc
Evelo Biosciences Inc
| Current Assets | 18.9m |
| Cash & Short-Term Investments | 17.3m |
| Other Current Assets | 1.6m |
| Non-Current Assets | 1.7m |
| PP&E | 900k |
| Other Non-Current Assets | 800k |
| Current Liabilities | 39.8m |
| Accounts Payable | 500k |
| Accrued Liabilities | 4.6m |
| Other Current Liabilities | 34.7m |
| Non-Current Liabilities | 7.5m |
| Other Non-Current Liabilities | 7.5m |
Balance Sheet
Evelo Biosciences Inc
Evelo Biosciences Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
16
|
38
|
93
|
78
|
69
|
69
|
48
|
|
| Cash |
1
|
13
|
1
|
2
|
5
|
2
|
1
|
|
| Cash Equivalents |
15
|
25
|
92
|
76
|
64
|
67
|
47
|
|
| Short-Term Investments |
0
|
0
|
55
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
4
|
3
|
2
|
3
|
4
|
|
| Total Current Assets |
16
|
39
|
152
|
81
|
71
|
71
|
52
|
|
| PP&E Net |
3
|
4
|
7
|
8
|
18
|
16
|
12
|
|
| PP&E Gross |
3
|
4
|
7
|
8
|
18
|
16
|
12
|
|
| Accumulated Depreciation |
1
|
1
|
2
|
4
|
6
|
8
|
9
|
|
| Other Long-Term Assets |
0
|
2
|
1
|
2
|
1
|
1
|
1
|
|
| Total Assets |
19
N/A
|
44
+135%
|
160
+265%
|
91
-43%
|
91
0%
|
88
-3%
|
64
-27%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
1
|
2
|
1
|
1
|
2
|
2
|
|
| Accrued Liabilities |
0
|
2
|
5
|
9
|
18
|
15
|
10
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
0
|
3
|
0
|
1
|
1
|
0
|
|
| Total Current Liabilities |
2
|
4
|
9
|
10
|
20
|
17
|
12
|
|
| Long-Term Debt |
10
|
10
|
12
|
20
|
30
|
47
|
44
|
|
| Other Liabilities |
1
|
1
|
1
|
1
|
10
|
15
|
13
|
|
| Total Liabilities |
13
N/A
|
15
+14%
|
23
+55%
|
31
+34%
|
60
+96%
|
79
+32%
|
69
-12%
|
|
| Equity | ||||||||
| Common Stock |
34
|
84
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
28
|
56
|
113
|
199
|
293
|
415
|
529
|
|
| Additional Paid In Capital |
0
|
2
|
250
|
259
|
323
|
423
|
524
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
6
N/A
|
29
+427%
|
137
+372%
|
60
-56%
|
31
-49%
|
9
-71%
|
5
N/A
|
|
| Total Liabilities & Equity |
19
N/A
|
44
+135%
|
160
+265%
|
91
-43%
|
91
0%
|
88
-3%
|
64
-27%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
2
|
2
|
3
|
6
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
